79 related articles for article (PubMed ID: 24368234)
1. Response to "Understanding CYP2D6 and its role in tamoxifen metabolism".
Kaplan M; Mahon SM
Oncol Nurs Forum; 2014 Jan; 41(1):12. PubMed ID: 24368234
[No Abstract] [Full Text] [Related]
2. Understanding CYP2D6 and its role in tamoxifen metabolism.
Smith EC
Oncol Nurs Forum; 2013 Nov; 40(6):547-8. PubMed ID: 24161632
[TBL] [Abstract][Full Text] [Related]
3. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen pharmacogenetics moves closer to reality.
Garber K
J Natl Cancer Inst; 2005 Mar; 97(6):412-3. PubMed ID: 15770000
[No Abstract] [Full Text] [Related]
5. A hot flash on tamoxifen metabolism.
Goetz MP; Loprinzi CL
J Natl Cancer Inst; 2003 Dec; 95(23):1734-5. PubMed ID: 14652227
[No Abstract] [Full Text] [Related]
6. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Chlebowski RT; Col N
J Natl Cancer Inst; 2008 Sep; 100(18):1331-2; author reply 132-3. PubMed ID: 18780870
[No Abstract] [Full Text] [Related]
7. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Ponzone R; Biglia N; Sismondi P
J Natl Cancer Inst; 2004 Jun; 96(11):883-4; author reply 884-5. PubMed ID: 15173274
[No Abstract] [Full Text] [Related]
8. [CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients].
Barrière J; Formento JL; Milano G; Ferrero JM
Bull Cancer; 2010 Mar; 97(3):311-20. PubMed ID: 20123649
[TBL] [Abstract][Full Text] [Related]
9. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
Van Poznak CH; Hayes DF
J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
[No Abstract] [Full Text] [Related]
10. Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.
Decaudin D; Etienne MC; De Cremoux P; Maciorowski Z; Vantelon JM; Voog E; Urien S; Tran-Perennou C; Renée N; Vielh P; Némati F; Pouillart P
J Natl Cancer Inst; 2004 Apr; 96(8):636-7. PubMed ID: 15100346
[No Abstract] [Full Text] [Related]
11. Tamoxifen, antidepressants, and CYP2D6: the conundrum continues.
Holzman D
J Natl Cancer Inst; 2009 Oct; 101(20):1370-1. PubMed ID: 19797723
[No Abstract] [Full Text] [Related]
12. CYP2D6 and tamoxifen: awaiting the denouement.
Brauch HB; Schroth W; Ingle JN; Goetz MP
J Clin Oncol; 2011 Dec; 29(34):4589-90; author reply 4590-1. PubMed ID: 22042960
[No Abstract] [Full Text] [Related]
13. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.
Bonanni B; Macis D; Maisonneuve P; Johansson HA; Gucciardo G; Oliviero P; Travaglini R; Muraca MG; Rotmensz N; Veronesi U; Decensi AU
J Clin Oncol; 2006 Aug; 24(22):3708-9; author reply 3709. PubMed ID: 16877740
[No Abstract] [Full Text] [Related]
14. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Ratliff B; Dietze EC; Bean GR; Moore C; Wanko S; Seewaldt VL
J Natl Cancer Inst; 2004 Jun; 96(11):883; author reply 884-5. PubMed ID: 15173275
[No Abstract] [Full Text] [Related]
15. Emphasizing the value of phenotyping in patients receiving tamoxifen.
Opdam FL; Dezentje VO; den Hartigh J; Guchelaar HJ; Gelderblom H
J Clin Oncol; 2012 Feb; 30(4):464; author reply 465. PubMed ID: 22184383
[No Abstract] [Full Text] [Related]
16. Personalized tamoxifen: what is the best way forward?
Rae JM
J Clin Oncol; 2011 Aug; 29(24):3206-8. PubMed ID: 21768456
[No Abstract] [Full Text] [Related]
17. Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
Antunes MV; Timm TA; de Oliveira V; Staudt DE; Raymundo S; Gössling G; Biazús JV; Cavalheiro JA; Rosa DD; Wallemacq P; Haufroid V; Linden R; Schwartsmann G
Ther Drug Monit; 2015 Dec; 37(6):733-44. PubMed ID: 25853922
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene.
Novillo A; Romero-Lorca A; Gaibar M; Rubio M; Fernández-Santander A
Pharmacogenomics J; 2017 Mar; 17(2):109-111. PubMed ID: 27698402
[No Abstract] [Full Text] [Related]
19. Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.
Safgren SL; Suman VJ; Kosel ML; Gilbert JA; Buhrow SA; Black JL; Northfelt DW; Modak AS; Rosen D; Ingle JN; Ames MM; Reid JM; Goetz MP
Pharmacogenet Genomics; 2015 Apr; 25(4):157-63. PubMed ID: 25714002
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
Zembutsu H
Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
